Less than a tenth of people who could benefit from obesity jabs such as Wegovy can access them, caution the World Health Organization as it publishes its inaugural recommendations on the therapies.
Considering over a billion individuals worldwide now living with obesity, it is urging broader and more equitable availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a lifelong illness that can be addressed with comprehensive and lifelong care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to universal access to the injections that can help people shift significant weight, notes the agency.
GLP-1 Therapy Supply Crisis
Even in the present best projected scenario, the manufacturing of these medications might only reach around 100 million people – under 10% of those who need them, per the health organization.
The recommendation urges countries and companies to widen availability, through approaches like voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs replicate a natural hormone to delay gastric emptying, curb appetite and increase satiety so users consume fewer calories.
Individuals commonly begin shedding pounds in the initial weeks of beginning the regular doses.
Studies indicates users may see weight return within a year of halting the medication, when their normal appetite return.
Being overweight or obese elevates your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity impacts people in all nations and was responsible for millions of deaths worldwide in 2024, as per the WHO.
